MAP2K7 and COVID-19: Our results support the idea that MEK inhibitors as a drug class may suppress COVID-19 infectivity factors while allowing (or in some cases boosting) NK-mediated (but not T-cell mediated) killing of target cells and suppressing inflammatory cytokines.